Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Prostatic Neoplasms 16Neoplasm Metastasis 16Urinary Bladder Neoplasms 13Neoplasms 9Clear-cell metastatic renal cell carcinoma 6Breast Neoplasms 5Kidney Diseases 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Urogenital Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Gastrointestinal Stromal Tumors 3Carcinoma 3Stomach Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2

Interventions

belzutifan 1Sunitinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangioblastoma × Sunitinib × Genitourinary × Clear all
NCT00330564 2024-06-27

Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 5 charts
Genitourinary

Carcinoma, Renal Cell, Cysts, von Hippel-Lindau Disease, Neoplasms, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡